Pharmaceutical compositions
First Claim
Patent Images
1. In combination:
- tumour necrosis factor (TNF) and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof, for simultaneous, separate or sequential use for treatment of patients suffering from medical conditions mediated by TNF.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides products containing tumour necrosis factor (TNF), and taurolidine and/or taurultam as a combined preparation for simultaneous, separate or sequential use for treatment of patients suffering from medical conditions mediated by TNF.
-
Citations
8 Claims
-
1. In combination:
- tumour necrosis factor (TNF) and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof, for simultaneous, separate or sequential use for treatment of patients suffering from medical conditions mediated by TNF.
- View Dependent Claims (2)
- 3. A method of treatment of medical conditions mediated by TNF comprising administering to a patient suffering from one or more said conditions effective amounts of TNF and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof.
-
5. A pharmaceutical composition comprising TNF and a member selected from the group consisting of taurolidine, taurultam and a mixture thereof.
-
6. A process of manufacturing a pharmaceutical composition, wherein TNF is admixed with a member selected from the group consisting of taurolidine, taurultam and a mixture thereof.
-
7. A method of reducing toxic effects of TNF in a human or non-human animal body, comprising administering to a human or non-human animal body at least one member selected from the group consisting of taurolidine, taurultam, and a mixture thereof, so as to reduce toxic effects of TNF in said body.
-
8. A method of treatment of a patient suffering from TNF-producing tumor or obstructive jaundice, thereby resulting in a chronic, detectable amount of TNF in the patient'"'"'s blood comprising administering an effective amount of a member selected from the group consisting of taurolidine, taurultam or a mixture thereof, to the patient.
Specification